Table 2.
Characteristics of patients with coagulation factor abnormalities and corresponding control subjects.
| Subjects | Deficiency | Age (y) | Male/female | Platelets (109/L) | Haematocrit (%) | Medication | Factor level | Refs. |
|---|---|---|---|---|---|---|---|---|
| Ctrl 1–10 | none | 30–51 | 5 M, 5F | 214–248 | 40.2–45.4 | None | Normal | n.a |
| Pat 1 | FXII | 60 | M | 306 | 48.8 | Aspirin | < 1% FXII | n.a |
| Pat 2 | FXII | 44 | F | 198 | 33.3 | None | < 1% FXII | n.a |
| Pat 3 | FXI | 18 | M | 260 | 44.1 | None | 19% FXI | n.a |
| Pat 4 | FXI | 31 | F | 292 | 40.2 | None | 33% FXI | n.a |
| Pat 5 | FV | 72 | F | 257 | 34.9 | None | < 5% FV | 22 |
| Pat 6 | FV | 75 | F | 132 | 38.8 | None | < 5% FV | 22 |
| Pat 7 | FV-Leiden | 48 | F | 257 | 38.6 | None | F5 1691G → A | 45 |
| Pat 8 | FV-Leiden | 38 | F | 267 | 37.7 | None | F5 1691G → A | 45 |
aConfirmed mutation in SHBG (sex hormone binding globulin) region (unpublished).